CapsoVision (NASDAQ:CV) Shares Gap Down – Should You Sell?

CapsoVision, Inc. (NASDAQ:CV)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $11.80, but opened at $10.78. CapsoVision shares last traded at $12.38, with a volume of 1,797,496 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Benchmark restated a “speculative buy” rating on shares of CapsoVision in a research report on Friday, November 14th. Roth Capital set a $7.00 target price on shares of CapsoVision in a research note on Tuesday, November 4th. Zacks Research raised shares of CapsoVision to a “hold” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CapsoVision presently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

CapsoVision Stock Up 23.1%

The stock has a 50-day moving average of $5.35.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $3.54 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund acquired a new stake in shares of CapsoVision, Inc. (NASDAQ:CV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,114 shares of the company’s stock, valued at approximately $34,000.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.